VCP
GSK icon

Verus Capital Partners’s GSK GSK Stock Holding History

Verus Capital Partners’s Portfolio GSK Stock Details GSK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-4,232
Closed -$230K – 294
2022
Q2 		$230K Hold
4,232
– – 0.05% 252
2022
Q1 		$232K Buy
+4,232
New +$230K 0.04% 280
2020
Q1 		$61K Hold
1,297
– – 0.02% 437
2019
Q4 		$76K Buy
+1,297
New +$72.1K 0.02% 460

Other funds holding GSK

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Verus Capital Partners's GSK Position: Q3 2022 in Review

Verus Capital Partners sold out of GSK (GSK) in Q3 2022, closing a stake of 4,232 shares — an estimated $230K sold.

Verus Capital Partners first reported a position in GSK in Q4 2019 and held it in 4 quarters. The position peaked at $232K in Q1 2022. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.

  • Verus Capital Partners reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
  • Verus Capital Partners sold 4,232 GSK shares in Q3 2022, an estimated $230K.
  • Verus Capital Partners first reported a position in GSK in Q4 2019 and held it in 4 quarters.
  • Verus Capital Partners's GSK position peaked at $232K in Q1 2022.
  • 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.

Based on Verus Capital Partners's 13F filing for Q3 2022, filed 15 Nov 2022.